Arman Soroor, Soheilimehr Ali, Maracy Mohammad Reza
Department of Psychiatry, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2017 Feb 22;6:11. doi: 10.4103/2277-9175.200786. eCollection 2017.
This study was designed to investigating the effect of combining D-cycloserine (DCS) and cognitive-behavioral therapy (CBT) on adolescent with at least one type of anxiety disorders.
The present study was conducted as a double-blind randomized controlled trial on 36 adolescent with anxiety disorders. Patients were assessed in two groups. In addition to 4 sessions of weekly CBT in both groups; case group, received a 50-mg DCS capsules, control group, received Placebo daily for a month. Patients received DCS capsules or placebo 1 h before sessions of CBT. Age, sex, kind of anxiety disorders "screen for child anxiety related disorders (SCARED)" and "cognitive abilities test (CATS)" scores were evaluated and compared between groups.
The mean age of the studied patients (29 females (80.6%) and 7 males (19.4%)) was 14.1 ± 1.8 years. The most frequent anxiety disorder among the study population was generalized social disorder (GAD) (77.7%). Age, sex and the frequency of anxiety disorders were not statistically significant between the study groups ( > 0.05). The mean score of "SCARED" and "CATS" at before starting the treatment, after treatment and three month after the treatment were not statistically significant between groups ( > 0.05). Also, decrease in values of "SCARED" and "CATS" during the evaluation time periods was not statistically significant between groups ( > 0.05).
Findings of this study showed that there has been no difference in symptoms improvement in adolescent with anxiety disorder who received treatment protocol including 4 sessions of CBT, weekly, together with 50 mgs of DCS compared to the patients of the control group.
本研究旨在调查联合使用D -环丝氨酸(DCS)和认知行为疗法(CBT)对患有至少一种焦虑症的青少年的影响。
本研究作为一项双盲随机对照试验,对36名患有焦虑症的青少年进行。患者被分为两组进行评估。除了两组均每周进行4次CBT治疗外;病例组每天服用50毫克DCS胶囊,对照组每天服用安慰剂,为期一个月。患者在每次CBT治疗前1小时服用DCS胶囊或安慰剂。对两组患者的年龄、性别、焦虑症类型(儿童焦虑相关障碍筛查量表(SCARED))和认知能力测试(CATS)分数进行评估和比较。
研究患者的平均年龄为14.1±1.8岁,其中女性29名(80.6%),男性7名(19.4%)。研究人群中最常见的焦虑症是广泛性社交障碍(GAD)(77.7%)。研究组之间的年龄、性别和焦虑症发生率无统计学意义(P>0.05)。治疗开始前、治疗后和治疗后三个月时,两组的“SCARED”和“CATS”平均分数无统计学意义(P>0.05)。此外,在评估时间段内,两组“SCARED”和“CATS”值的下降也无统计学意义(P>0.05)。
本研究结果表明,与对照组患者相比,接受每周4次CBT治疗方案并联合50毫克DCS治疗的焦虑症青少年在症状改善方面没有差异。